Renaud Vaillant Email & Phone Number

Paris, Fr

Cambridge, Us

Paris, Île-De-France, Fr

Corporate cards reinvented. Mooncard provides the dream payment and expense solution for employees, CEOs, CFOs and entrepreneurs.http://www.mooncard.co

Honing Biosciences is a spin-off of the Curie Institute in Paris.Honing is developing a technology allowing on-demand modulation of proteins like CARs. The CAR is retained by a hook in the endoplasmic reticulum of T-cells and released upon biotin oral or IV administration. The technology is promising and versatile.

London, Gb

Ixaka develops proprietary cell and gene therapies.Our therapies work by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Our proprietary technologies offers potentially dramatic improvements across a wide range of serious diseases including degenerative cardiovascular diseases, but also cancers (both blood-borne and solid tumors), rare genetic disorders, neurological and autoimmune diseases.It includes the development of an in vivo gene delivery platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced (since the acquisition of aratinga.bio).The lentivector - encoding for the Chimeric Antigen Receptor - is coated with a polymeric envelope. The anti-CD3 targeting moiety grafted at the surface of the polymer directs the synthetic vector towards the T-cells. The genetic modification to express the CAR is directly generated in the patient.

aratinga.bio is a preclinical-stage immunotherapy biotech company developing novel immunotherapies to treat cancer. We want to harness the immune system to target and kill cancer cells. aratinga.bio is developing an in vivo gene delivery platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced.The lentivector - encoding for the Chimeric Antigen Receptor - is coated with a polymeric envelope. The anti-CD3 targeting moiety grafted at the surface of the polymer directs the synthetic vector towards the T-cells.The genetic modification to express the CAR is directly generated in the patient.

Nanterre, Na, Fr

Company founded in 1988, listed on the Euronext Stock Exchange since 2006.SES-imagotag, a BOE Technology Group company, has been the trusted partner of retailers for in-store digital technology.SES-imagotag is the worldwide leader in smart digital labels and pricing automation and has developed a comprehensive IoT and digital platform that delivers a complete set of services to retailers.The SES-imagotag solution enables retailers to connect and digitally transform their physical stores; automate low-value-added processes; improve operational efficiency; inform and serve customers; ensure information integrity to continuously optimize on-hand inventory; prevent stock-outs and waste and create an omnichannel service platform that builds loyalty and meets evolving consumer expectations.

Paris, Île-De-France, Fr

THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute. Based on its lentiviral vector technology platform, THERAVECTYS develops innovative immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.Capitalizing over 15 years of fundamental research in the field of lentiviral vectors, the company has built a broad and robust intellectual property position in addition to worldwide and exclusive licenses secured from institutions including Institut Pasteur and Institut Curie.The company has recently successfully completed a Phase I/II confirming both safety & immunogenicity of the lentiviral vector technology. THERAVECTYS lead oncology lentivector immunotherapy will enter clinical trials in 2015 while the company’s CAR T-cell therapies are in the preclinical stage.

Paris, Île-De-France, Fr

THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute. Based on its lentiviral vector technology platform, THERAVECTYS develops innovative immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.Capitalizing over 15 years of fundamental research in the field of lentiviral vectors, the company has built a broad and robust intellectual property position in addition to worldwide and exclusive licenses secured from institutions including Institut Pasteur and Institut Curie.The company has recently successfully completed a Phase I/II confirming both safety & immunogenicity of the lentiviral vector technology. THERAVECTYS lead oncology lentivector immunotherapy will enter clinical trials in 2015 while the company’s CAR T-cell therapies are in the preclinical stage.

Fr

CRYOLOG develops original solutions for the traceability of temperature-sensitive products.These solutions make it possible to check at a glance, and over the life span of the product, whether the storage conditions have maintained the product’s freshness.The products and services offered by CRYOLOG respond to the requirements of our clients’ in the agri-food, health and non-domestic catering sectors, for high performance and ease of use and implementation. These solutions also take into account the legitimate expectations of consumers who are more and more demanding in terms of the quality and the safety of products.The use of microbiology to model the evolution of the products being traced is a technological revolution. This technological advance, which is only offered by CRYOLOG, means that we can provide our clients with products which are precisely adapted to their requirements.

Master 2 (M2), Master Of Science In It & Telecom

Master Of Science

Bachelor Of Science In Maths & Physics (Psi*)

Scientific Baccalaureate